United States NGS-Based RNA Sequencing Market to hit US$ 4.5 Billion by 2033, Driven by Expanding Precision Medicine and Advancements in Genomic Technologies

The NGS-Based RNA Sequencing Market size reached USD 4.4 billion in 2025 and is estimated to reach USD 15.0 billion by 2033, growing at a CAGR of 19% during the forecast period (2026-2033). Growth is driven by increasing demand for advanced genomic analysis and precision medicine. Rising adoption of next-generation sequencing technologies in research and clinical diagnostics is boosting market expansion. The growing prevalence of genetic disorders and cancer is further supporting demand. Additionally, advancements in sequencing technologies and data analysis tools are enhancing efficiency and accuracy. Expanding applications in drug discovery, biomarker identification, and personalized healthcare are also contributing to strong market growth.

Download PDF Sample Report:
https://www.datamintelligence.com/download-sample/ngs-based-rna-sequencing-market?prasad

NGS Based RNA Sequencing Market Major Players:

Illumina, Inc.

Illumina is the global leader in next-generation sequencing (NGS) technologies, with dominant positioning in RNA sequencing applications. In 2025, Illumina reported revenue of USD 4.8 billion, driven by strong demand for genomic sequencing platforms and consumables. In the NGS-based RNA sequencing market, Illumina plays a major role through its high-throughput sequencing systems and reagent kits that enable accurate transcriptome analysis, gene expression profiling, and biomarker discovery. Its platforms are widely used in research, clinical diagnostics, and drug development, making it a cornerstone provider in genomics-driven precision medicine.

Oxford Nanopore Technologies

Oxford Nanopore Technologies is a leading innovator in real-time sequencing technologies with strong capabilities in RNA sequencing. In 2025, the company reported revenue of USD 0.3 billion, reflecting growing adoption of its portable and scalable sequencing platforms. In the NGS-based RNA sequencing market, Oxford Nanopore plays a key role by offering long-read sequencing technologies that enable direct RNA sequencing without amplification. Its solutions provide unique advantages in transcript structure analysis, isoform detection, and real-time data generation, making them valuable for advanced genomic research and clinical applications.

Agilent Technologies, Inc.

Agilent Technologies is a global leader in life sciences, diagnostics, and analytical instrumentation, with strong involvement in NGS workflows. In 2025, Agilent reported revenue of USD 6.7 billion, supported by its diagnostics and genomics segments. In the NGS-based RNA sequencing market, Agilent plays a significant role by providing sample preparation solutions, target enrichment kits, and quality control systems that support RNA sequencing workflows. Its technologies are widely used in academic research, clinical laboratories, and pharmaceutical development, enabling high-quality and reliable RNA sequencing analysis.

Find the Right Partner to Accelerate Your Growth Today with Our Latest Report:
https://www.datamintelligence.com/partner-identification-enquiry/ngs-based-rna-sequencing-market?prasad

United States: Recent Industry Developments

✅ In March 2026, Illumina, Inc. expanded NGS-based RNA sequencing platforms for clinical research. The innovation improves sequencing accuracy. Illumina continues advancing genomics technologies.

✅ In February 2026, Thermo Fisher Scientific enhanced RNA sequencing workflows using next-generation sequencing technologies. The development improves throughput. Thermo Fisher continues strengthening genomics solutions.

✅ In January 2026, Pacific Biosciences expanded long-read RNA sequencing capabilities. The initiative improves transcriptome analysis. PacBio continues advancing sequencing innovation.

✅ In December 2025, Agilent Technologies enhanced RNA sequencing sample preparation solutions. The development improves efficiency. Agilent continues strengthening genomics tools.

Japan: Recent Industry Developments

✅ In March 2026, Takara Bio Inc. expanded RNA sequencing solutions using NGS technologies. The innovation improves research outcomes. Takara Bio continues advancing genomics.

✅ In February 2026, Fujifilm Corporation enhanced sequencing technologies for life sciences research. The development improves accuracy. Fujifilm continues strengthening biotech portfolio.

✅ In January 2026, Shimadzu Corporation expanded analytical tools supporting RNA sequencing workflows. The initiative improves performance. Shimadzu continues advancing life sciences.

✅ In December 2025, Hitachi, Ltd. enhanced bioinformatics platforms supporting RNA sequencing. The development improves data analysis. Hitachi continues strengthening healthcare IT.

Segment Covered in the NGS Based RNA Sequencing Market:

By Type: Adeno-Associated Viral (AAV) Vectors
Adeno-associated viral (AAV) vectors dominate the viral vector manufacturing market due to their strong safety profile, low immunogenicity, and effectiveness in delivering genes for long-term expression. AAV vectors are widely used in gene therapy applications, particularly for rare genetic disorders.
AAV vectors account for approximately 44% of the total market. Based on a global market size assumption of USD 7.6 billion in 2025, this translates to an estimated segment value of USD 3.3 billion. Growth is driven by increasing approvals of gene therapies, rising investment in biotechnology, and expanding clinical pipelines.

By Disease: Cancer
Cancer represents the largest disease segment due to the growing use of viral vectors in oncology treatments, including CAR-T cell therapies and oncolytic virus therapies. Viral vectors play a critical role in delivering genetic material for targeted cancer treatment.
This segment accounts for approximately 39% of the total market. Based on the USD 7.6 billion global market size in 2025, this corresponds to an estimated value of USD 3.0 billion. Growth is driven by increasing cancer prevalence, rising adoption of advanced therapies, and strong R&D investment in oncology.

By Application: Gene Therapy
Gene therapy dominates the application segment due to its transformative potential in treating genetic disorders and chronic diseases. Viral vectors are essential for delivering therapeutic genes into patient cells, making them a cornerstone of gene therapy development.
This segment accounts for approximately 68% of the total market. Based on the USD 7.6 billion global market size in 2025, this corresponds to an estimated value of USD 5.2 billion. Growth is driven by increasing number of gene therapy approvals, expanding clinical trials, and strong investment in advanced therapeutics.

By End User: Pharmaceutical and Biopharmaceutical Companies
Pharmaceutical and biopharmaceutical companies dominate the market as they are the primary developers and manufacturers of gene therapies and vaccines. These organizations invest heavily in viral vector production capabilities and partnerships.
This segment accounts for approximately 61% of the total market. Based on the USD 7.6 billion global market size in 2025, this corresponds to an estimated value of USD 4.6 billion. Growth is driven by increasing R&D spending, strategic collaborations, and rising demand for scalable manufacturing solutions.

Market Segmentation

The Viral Vector Manufacturing Market is segmented by type into retroviral vectors, adenoviral vectors, adeno-associated viral vectors, and other viral vectors; by disease into cancer, genetic disorders, infectious diseases, and other diseases; by application into gene therapy and vaccinology; by end user into pharmaceutical & biopharmaceutical companies and research institutes; and by region into North America, Latin America, and Europe.

Get Customization in the report as per your requirements:
https://www.datamintelligence.com/customize/ngs-based-rna-sequencing-market?prasad

Regional Analysis

North America
North America is the leading market due to advanced biotechnology infrastructure, strong presence of key industry players, and high investment in gene therapy research. The region is led by the United States.
The North American market is estimated at approximately USD 3.2 billion in 2025, accounting for about 42% of the global market. Growth is driven by increasing gene therapy approvals, strong funding environment, and advanced manufacturing capabilities.

Europe
Europe is a significant market supported by strong research ecosystem, regulatory support, and increasing adoption of advanced therapies. Key contributors include Germany, France, and the United Kingdom.
The European market is valued at approximately USD 2.6 billion in 2025, representing about 34% of the global market. Growth is driven by expanding clinical trials, government funding, and growing biotechnology sector.

Latin America
Latin America is an emerging market driven by improving healthcare infrastructure, increasing research activities, and gradual adoption of advanced therapies, with Brazil and Mexico as key contributors.
The market is estimated at approximately USD 1.8 billion in 2025, accounting for about 24% of the global market. Growth is supported by rising investment in biotechnology and increasing awareness of gene therapies.

Data-Driven Research Methodology for the NGS Based RNA Sequencing Market:

Our research process for the NGS Based RNA Sequencing Market at DataM Intelligence combines rigorous primary and secondary research to ensure accurate and reliable insights. We engage with industry experts, key stakeholders, and validated data sources to capture real-time market dynamics. Advanced analytical tools and proprietary models are applied to forecast trends, competitive landscapes, and growth opportunities. Each report undergoes multi-level validation to deliver actionable intelligence that supports strategic decision-making.

Purchase the Exclusive Report:
https://www.datamintelligence.com/buy-now-page?report=ngs-based-rna-sequencing-market?prasad

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Contact Us-
Fabian
DataM Intelligence 4market Research LLP
6th Floor, M2 Tech Hub, DataM Intelligence 4market Research LLP, Lalitha Nagar, Habsiguda, Secunderabad, Hyderabad, Telangana 500039
USA: +1 877-441-4866
UK: +44 161-870-5507
Email: fabian@datamintelligence.com

About Us
DataM Intelligence is a market research and consulting firm that delivers comprehensive end-to-end business solutions, covering everything from in-depth research to strategic consulting. The company leverages key industry trends, insights, and developments to provide fast, reliable, and actionable solutions tailored to diverse client requirements.
It offers both syndicated and customized research reports supported by a strong and robust methodology. With an extensive database comprising 9000+ reports across 40+ industry domains, DataM Intelligence serves over 200 companies in more than 50 countries, helping organizations access critical business intelligence that drives informed decision-making and sustainable growth.

This release was published on openPR.